Cargando…
Endoscopic recommendations for colorectal cancer screening and surveillance in patients with inflammatory bowel disease: Review of general recommendations
Screening for colorectal cancer (CRC) in patients with inflammatory bowel disease (IBD) is recommended by all scientific societies. However, there are differences in the recommendations they make regarding screening and surveillance. We address a series of questions that come up in the daily clinica...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5483417/ https://www.ncbi.nlm.nih.gov/pubmed/28690768 http://dx.doi.org/10.4253/wjge.v9.i6.255 |
_version_ | 1783245753252052992 |
---|---|
author | Huguet, Jose María Suárez, Patricia Ferrer-Barceló, Luis Ruiz, Lucía Monzó, Ana Durá, Ana Belén Sempere, Javier |
author_facet | Huguet, Jose María Suárez, Patricia Ferrer-Barceló, Luis Ruiz, Lucía Monzó, Ana Durá, Ana Belén Sempere, Javier |
author_sort | Huguet, Jose María |
collection | PubMed |
description | Screening for colorectal cancer (CRC) in patients with inflammatory bowel disease (IBD) is recommended by all scientific societies. However, there are differences in the recommendations they make regarding screening and surveillance. We address a series of questions that come up in the daily clinical practice of a physician. The first two questions that are raised are: (1) Who should be offered screening for CRC? and (2) When should the first colonoscopy be performed? The next step is to decide who should undergo endoscopic surveillance and at what intervals they should be performed. Chromoendoscopy is emerging as the recommended endoscopic technique for screening and surveillance. The terminology for describing lesions detected with endoscopy is also changing. The management of visible lesions or non-visible dysplasia is also a motive for the review. We end the review by addressing the follow-up for endoscopically resected lesions. These questions often cannot be answered easily due to the varying degrees of evidence available; therefore, we have made some general recommendations based on those made by the various guidelines and consensuses. The first screening colonoscopy should be offered 8 years after a IBD diagnosis and we recommend that patients be stratified according to the individual risk for each for endoscopic surveillance intervals. |
format | Online Article Text |
id | pubmed-5483417 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-54834172017-07-09 Endoscopic recommendations for colorectal cancer screening and surveillance in patients with inflammatory bowel disease: Review of general recommendations Huguet, Jose María Suárez, Patricia Ferrer-Barceló, Luis Ruiz, Lucía Monzó, Ana Durá, Ana Belén Sempere, Javier World J Gastrointest Endosc Minireviews Screening for colorectal cancer (CRC) in patients with inflammatory bowel disease (IBD) is recommended by all scientific societies. However, there are differences in the recommendations they make regarding screening and surveillance. We address a series of questions that come up in the daily clinical practice of a physician. The first two questions that are raised are: (1) Who should be offered screening for CRC? and (2) When should the first colonoscopy be performed? The next step is to decide who should undergo endoscopic surveillance and at what intervals they should be performed. Chromoendoscopy is emerging as the recommended endoscopic technique for screening and surveillance. The terminology for describing lesions detected with endoscopy is also changing. The management of visible lesions or non-visible dysplasia is also a motive for the review. We end the review by addressing the follow-up for endoscopically resected lesions. These questions often cannot be answered easily due to the varying degrees of evidence available; therefore, we have made some general recommendations based on those made by the various guidelines and consensuses. The first screening colonoscopy should be offered 8 years after a IBD diagnosis and we recommend that patients be stratified according to the individual risk for each for endoscopic surveillance intervals. Baishideng Publishing Group Inc 2017-06-16 2017-06-16 /pmc/articles/PMC5483417/ /pubmed/28690768 http://dx.doi.org/10.4253/wjge.v9.i6.255 Text en ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Minireviews Huguet, Jose María Suárez, Patricia Ferrer-Barceló, Luis Ruiz, Lucía Monzó, Ana Durá, Ana Belén Sempere, Javier Endoscopic recommendations for colorectal cancer screening and surveillance in patients with inflammatory bowel disease: Review of general recommendations |
title | Endoscopic recommendations for colorectal cancer screening and surveillance in patients with inflammatory bowel disease: Review of general recommendations |
title_full | Endoscopic recommendations for colorectal cancer screening and surveillance in patients with inflammatory bowel disease: Review of general recommendations |
title_fullStr | Endoscopic recommendations for colorectal cancer screening and surveillance in patients with inflammatory bowel disease: Review of general recommendations |
title_full_unstemmed | Endoscopic recommendations for colorectal cancer screening and surveillance in patients with inflammatory bowel disease: Review of general recommendations |
title_short | Endoscopic recommendations for colorectal cancer screening and surveillance in patients with inflammatory bowel disease: Review of general recommendations |
title_sort | endoscopic recommendations for colorectal cancer screening and surveillance in patients with inflammatory bowel disease: review of general recommendations |
topic | Minireviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5483417/ https://www.ncbi.nlm.nih.gov/pubmed/28690768 http://dx.doi.org/10.4253/wjge.v9.i6.255 |
work_keys_str_mv | AT huguetjosemaria endoscopicrecommendationsforcolorectalcancerscreeningandsurveillanceinpatientswithinflammatoryboweldiseasereviewofgeneralrecommendations AT suarezpatricia endoscopicrecommendationsforcolorectalcancerscreeningandsurveillanceinpatientswithinflammatoryboweldiseasereviewofgeneralrecommendations AT ferrerbarceloluis endoscopicrecommendationsforcolorectalcancerscreeningandsurveillanceinpatientswithinflammatoryboweldiseasereviewofgeneralrecommendations AT ruizlucia endoscopicrecommendationsforcolorectalcancerscreeningandsurveillanceinpatientswithinflammatoryboweldiseasereviewofgeneralrecommendations AT monzoana endoscopicrecommendationsforcolorectalcancerscreeningandsurveillanceinpatientswithinflammatoryboweldiseasereviewofgeneralrecommendations AT duraanabelen endoscopicrecommendationsforcolorectalcancerscreeningandsurveillanceinpatientswithinflammatoryboweldiseasereviewofgeneralrecommendations AT semperejavier endoscopicrecommendationsforcolorectalcancerscreeningandsurveillanceinpatientswithinflammatoryboweldiseasereviewofgeneralrecommendations |